Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $61
Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $61
尼德姆保持對revolution medicines的買入評級，將價格目標下調至61美元。
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $62 to $61.
Needham的分析師Ami Fadia維持Revolution Medicines (NASDAQ:RVMD)的買入評級，將目標價從62美元降至61美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。